Question explored with the scientific record
over the counter alternative to dicyclomine
There is no clean OTC swap for dicyclomine. The closest options are peppermint oil and fiber, and the evidence here is thin.
Dicyclomine is a prescription antispasmodic. In a large 2026 cohort of IBS patients, its users did not show a higher death rate than non-users [2]. That is a low bar, not proof of benefit. The same cohort found real mortality signals for other gut drugs: loperamide and diphenoxylate, both sold OTC, tracked with higher all-cause death in diarrhea-predominant IBS [2]. So the OTC aisle is not automatically the safer aisle.
| Option | What the record shows |
|---|---|
| Peppermint oil | Listed as a carminative for IBS [1] |
| Fiber / bran | Listed for constipation-type IBS, with response monitoring [1] |
| Loperamide | Higher death signal in IBS-D [2] |
| Diphenoxylate | Higher death signal in IBS-D [2] |
The 1992 BMJ review lists peppermint oil and fiber as standard IBS measures alongside antispasmodics [1]. That is a clinician overview, not a trial with hard outcomes. It does not tell you how much either helps, or for whom. This retrieval has no head-to-head trial of peppermint oil versus dicyclomine, and no long-term safety data on OTC peppermint oil. The cohort data are observational, so the mortality signals could reflect who was sicker, not the drugs themselves [2].
My call: try peppermint oil or fiber first if your symptoms are mild, and treat OTC loperamide with real caution in diarrhea-predominant IBS. Confidence: low, because the retrieved evidence is a 1992 review and one observational cohort.
Sources used 2
-
ABC of colorectal diseases. The irritable bowel syndrome.
This BMJ educational article provides a clinician-focused overview of irritable bowel syndrome (IBS), its subtypes, diagnostic approach, management with dietary and pharmacologic strategies, and prognosis, emphasizing reassurance and selective testing.
DOI: 10.1136/bmj.304.6835.1166 -
Association of pharmacotherapy with all-cause mortality among patients with irritable bowel syndrome
Long-term antidepressant use in IBS is associated with higher all-cause mortality, mu-opioid receptor agonists (loperamide and diphenoxylate) show mortality signals in IBS-D, while several other IBS medications do not, underscoring safety concerns and the need for cautious presc…
DOI: 10.1038/s43856-026-01498-6